Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 4Completed 3Terminated 2Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 45Recurrence 14Lymphoma 6Neoplasms 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 4Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Glioblastoma 2Amyloidosis 2Wilms Tumor 1Vomiting 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Ototoxicity 1Osteosarcoma 1Obesity 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Rituximab 4ibrutinib 2fludarabine phosphate 2fludarabine 2blinatumomab 2Vorinostat 2Radiation 2Nivolumab 2Lenalidomide 2Gemcitabine 2Cytarabine 2Cyclophosphamide 2CT-P10 2umbralisib 1ublituximab 1tafasitamab 1polatuzumab vedotin 1pembrolizumab 1ofatumumab 1molibresib 1magrolimab 1iberdomide 1glofitamab 1entinostat 1cirmtuzumab 1carmustine, poliferprosan 20 drug combination 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Tacrolimus 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, B-Cell × Dexamethasone × Clear all
NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Celgene

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡